As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Oaktree Acquisition Corp. III Life Sciences. The largest reported stake is Barclays PLC's, at 6.99%. 7 filings are on record since July 15, 2025 (Schedule 13G, August 13, 2026).
Sell to companies like Oaktree Acquisition Corp. III Life Sciences? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Decagon Asset Management LLP · Sole voting: 1,091,327 · Shared voting: 0 · Sole dispositive: 1,091,327 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Barclays PLC · Sole voting: 1,384,810 · Shared voting: 0 · Sole dispositive: 1,384,810 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-13
- · Reporting person: Fort Baker Capital Management LP · Sole voting: 0 · Shared voting: 1,000,000 · Sole dispositive: 0 · Shared dispositive: 1,000,000 · SCHEDULE 13G, 2026-05-15
- · Reporting person: The Goldman Sachs Group, Inc. · Sole voting: 0 · Shared voting: 1,228,500 · Sole dispositive: 0 · Shared dispositive: 1,228,500 · SCHEDULE 13G, 2026-05-11
- · Holder: Barclays PLC · Percent: 4.35% · SCHEDULE 13G/A
Oaktree Acquisition Corp. III Life Sciences has 7 Schedule 13D or 13G filings on record since 2025-07-15. 4 holders' latest filing reports 5% or more of class a ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Barclays PLC | 6.99% | 1,384,810 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
| The Goldman Sachs Group, Inc. | 6.2% | 1,228,500 | SCHEDULE 13G, 2026-05-11 | 2026-03-31 |
| Decagon Asset Management LLP | 5.52% | 1,091,327 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Fort Baker Capital Management LP | 5.1% | 1,000,000 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Millennium Management LLC | 1.4% | 277,689 | SCHEDULE 13G/A, 2025-07-15 | 2025-06-30 |
Holding shares or following this stake? See who's behind Oaktree Acquisition Corp. III Life Sciences and the warning signs.
Free to see. No signup.
Keep reading
More on Oaktree Acquisition Corp. III Life Sciences and the records around it.
Companies that share a holder
- Decagon Asset Management LLP also filed stake reports on 14 other companies: Alpex Acquisition Corp (Aug 2026), APEX Tech Acquisition Inc. (Aug 2026), Future Money Acquisition Corp (Aug 2026)
- Fort Baker Capital Management LP also filed stake reports on 26 other companies: Agriculture & Natural Solutions Acquisition Corp (Aug 2026), Bleichroeder Acquisition Corp. II (Aug 2026), Cartesian Growth Corp III (Aug 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
Watch Oaktree Acquisition Corp. III Life Sciences
Get an email when Oaktree Acquisition Corp. III Life Sciences files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Oaktree Acquisition Corp. III Life Sciences?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Oaktree Acquisition Corp. III Life Sciences: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oaktree Acquisition Corp. III Life Sciences covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Barclays PLC | 1,384,810 | 0 | 1,384,810 | 0 | SCHEDULE 13G, 2026-08-13 |
| The Goldman Sachs Group, Inc. | 0 | 1,228,500 | 0 | 1,228,500 | SCHEDULE 13G, 2026-05-11 |
| Goldman Sachs & Co. LLC | 0 | 1,228,500 | 0 | 1,228,500 | SCHEDULE 13G, 2026-05-11 |
| Decagon Asset Management LLP | 1,091,327 | 0 | 1,091,327 | 0 | SCHEDULE 13G, 2026-08-14 |
| Benjamin John Durham | 1,091,327 | 0 | 1,091,327 | 0 | SCHEDULE 13G, 2026-08-14 |
| Fort Baker Capital Management LP | 0 | 1,000,000 | 0 | 1,000,000 | SCHEDULE 13G, 2026-05-15 |
| Steven Patrick Pigott | 0 | 1,000,000 | 0 | 1,000,000 | SCHEDULE 13G, 2026-05-15 |
| Fort Baker Capital, LLC | 0 | 1,000,000 | 0 | 1,000,000 | SCHEDULE 13G, 2026-05-15 |
The latest filing identifies Oaktree Acquisition Corp. III Life Sciences by CUSIP G6717R104 and gives its principal executive office as 333 SOUTH GRAND AVENUE, 28TH FLOOR, LOS ANGELES, CA 90071 (SCHEDULE 13G, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | Millennium Management LLC | 1.4% | SCHEDULE 13G/A |
| 2025-08-12 | The Goldman Sachs Group, Inc. | 4.1% | SCHEDULE 13G/A |
| 2026-02-11 | Barclays PLC | 4.35% | SCHEDULE 13G/A |
| 2026-05-11 | The Goldman Sachs Group, Inc. | 6.2% | SCHEDULE 13G |
| 2026-05-15 | Fort Baker Capital Management LP | 5.1% | SCHEDULE 13G |
| 2026-08-13 | Barclays PLC | 6.99% | SCHEDULE 13G |
| 2026-08-14 | Decagon Asset Management LLP | 5.52% | SCHEDULE 13G |
Questions about who owns Oaktree Acquisition Corp. III Life Sciences
Who owns Oaktree Acquisition Corp. III Life Sciences?
On this page, 4 holders' latest ownership filings report 5% or more of Oaktree Acquisition Corp. III Life Sciences: Barclays PLC (6.99%, Schedule 13G, filed 2026-08-13), The Goldman Sachs Group, Inc. (6.2%, Schedule 13G, filed 2026-05-11), Decagon Asset Management LLP (5.52%, Schedule 13G, filed 2026-08-14) and Fort Baker Capital Management LP (5.1%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Oaktree Acquisition Corp. III Life Sciences?
By the share each holder's latest filing reports, the largest holders of Oaktree Acquisition Corp. III Life Sciences on this page are Barclays PLC (6.99%), The Goldman Sachs Group, Inc. (6.2%) and Decagon Asset Management LLP (5.52%).
When did Barclays PLC buy into Oaktree Acquisition Corp. III Life Sciences?
The filings give report dates, not purchase dates. The earliest filing from Barclays PLC on this page is the Schedule 13G/A, filed 2026-02-11, reporting 4.35%; its latest, Schedule 13G filed 2026-08-13, reports 6.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Oaktree Acquisition Corp. III Life Sciences
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 24, 2024 | IPO filing, Form 424B4 | — | IPO filings | Source |
| October 18, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 4, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Oaktree Acquisition Corp. III Life Sciences. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.